Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.

ABSTRACT:

Importance

De novo bullous pemphigoid (BP) is a rare immune-mediated adverse event from immune checkpoint inhibitors (ICIs) that can necessitate permanent discontinuation of the anticancer therapy, but the risk factors for developing this toxic effect are unknown.

Objective

To compare potential risk factors for BP in patients treated with ICIs who did and did not develop BP.

Design, setting, and participants

This cohort and nested propensity score-matched case-control study was conducted at the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Massachusetts General Hospital. All patients at these facilities with de novo BP after ICI treatment were compared with all patients on the cancer registry who were treated with ICIs between October 1, 2014, and De

SUBMITTER: Said JT 

PROVIDER: S-EPMC9008562 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature